Neuroscience
New Book Challenges Conventional Dementia Care, Advocates for Non-Invasive Gamma Stimulation
Mark L. Fox's 'The Memory Room' presents evidence that cognitive decline may be mitigated through 40 Hz gamma stimulation, based on MIT research and a clinical study showing cognitive improvement in all 41 participants.
Helus Pharma CMO to Speak at H.C. Wainwright Neuro Perspectives Conference
Helus Pharma's Chief Medical Officer will present at a key industry conference, highlighting the company's progress in developing novel treatments for depression and anxiety.
Microglia Protein Production Linked to Pediatric Brain Tumor Spread, Study Finds
Scientists discovered that microglia in the brain produce fibronectin proteins, enabling diffuse midline gliomas to spread, highlighting a potential therapeutic target for companies like CNS Pharmaceuticals.
Quantum BioPharma Advances Multiple Sclerosis Drug Candidate Lucid-MS and Commercial Product unbuzzd™
Quantum BioPharma's lead drug Lucid-MS targets nerve damage in multiple sclerosis, with a Phase 2 trial upcoming, while its alcohol metabolism product unbuzzd™ generates royalty revenue.
iOrganBio Adds Leading Neurobiologist Dr. Zhiping Pang to Scientific Advisory Board
iOrganBio appoints Dr. Zhiping Pang, a top expert in human neuron biology and neuropsychiatric disorders, to its Scientific Advisory Board, strengthening its position in AI-enabled human cell manufacturing for research and therapeutics.
Oragenics Advances Phase IIa Concussion Trial, Eyes CNS Device Licensing
Oragenics provided a shareholder update on its Phase IIa trial of ONP-002 for concussion in Australia, plans for U.S. regulatory meetings, and a letter of intent to license a complementary CNS medical device.
Quantum BioPharma Reaches Midpoint Enrollment in MS Imaging Study, Showing Encouraging Early Data
Quantum BioPharma announced that patient enrollment in its multiple sclerosis imaging study with Massachusetts General Hospital has reached 50%, with preliminary PET imaging data showing promising signals in acute MS lesions and potential sensitivity to gray matter lesions, which could accelerate development of MS therapies including its candidate Lucid-MS.
Oncotelic Therapeutics Featured in Editorial Highlighting Intranasal Drug Delivery for Alzheimer's and Biodefense
Oncotelic Therapeutics' intranasal nose-to-brain delivery platform, featured in a BioMedWire editorial, addresses key challenges in CNS drug delivery for Alzheimer's disease and biodefense research by bypassing the blood-brain barrier.
Oncotelic’s Intranasal Brain Delivery Platform Highlighted as CNS Drug Development Gains Urgency
Oncotelic Therapeutics featured in BioMedWire editorial for its nose-to-brain delivery platform that bypasses the blood-brain barrier, with rising Alzheimer’s cases and biodefense needs driving demand for such technologies.
Aclarion Adds First Private Practice Site in Los Angeles to CLARITY Trial
Aclarion announced the addition of Lanman Spinal Neurosurgery in Beverly Hills to its CLARITY trial, expanding enrollment beyond academic centers and highlighting growing interest in Nociscan for precise chronic low back pain diagnosis.
CNS Drug Delivery Innovations Address Critical Bottleneck in Biotech Market
Advancements in blood-brain barrier penetration technologies, such as Oncotelic's intranasal nose-to-brain system, are unlocking significant opportunities in the biotech sector by enabling targeted CNS therapies for diseases like Alzheimer's and bolstering biodefense preparedness.
Silo Pharma Launches Ibogaine-Based TBI Therapeutics Initiative
Silo Pharma announced a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury and related conditions, filing a provisional patent application.
Oncotelic Therapeutics Completes $12.5M Asset Transfer to Lunai Bioworks, Focusing on Nose-to-Brain Delivery for Alzheimer's and Biodefense
Oncotelic Therapeutics has transferred worldwide rights to its nose-to-brain delivery system for Alzheimer's and biodefense to Lunai Bioworks in exchange for $12.5 million in preferred stock, enabling it to monetize assets while retaining control for other indications like Parkinson's disease.
Brain Health Shaped by Lifetime Mental, Physical, Environmental and Lifestyle Factors, New AHA Statement Says
A new American Heart Association scientific statement highlights that brain health is influenced by a range of factors across the entire lifespan, including mental health, sleep, environment, and social conditions, offering opportunities for early intervention to reduce the risk of stroke, cognitive decline, and dementia.
Helus Pharma Appoints Robert Langer and Stephen Brannan to Scientific Advisory Board, Bolstering Neuroscience Pipeline
Helus Pharma adds renowned experts Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, strengthening its drug development capabilities for mental health treatments including major depressive disorder and generalized anxiety disorder.
Canadian Scientists Identify Brain Cells That Fuel Glioblastoma Growth
Researchers have discovered that certain brain cells previously thought to be passive support structures actively promote glioblastoma tumor growth, potentially opening new therapeutic avenues for one of the deadliest forms of brain cancer.
Memory Beads Inspired by 116-Year-Old's Habit Launch to Support Alzheimer's Research
A new tactile brain health tool called Peter's Memory Beads, inspired by a 116-year-old man's daily routine, has launched with all proceeds supporting Alzheimer's Association research and services.
Two Neuroscientists Awarded 2026 Ralph L. Sacco Scholarships for Brain Health Research
The American Academy of Neurology and the American Heart Association have awarded $150,000 scholarships to Sarah Kettlety and Cali McEntee to study concussion recovery in children and the effects of exercise on brain aging, respectively.
Molecular Testing Gains Importance in Complex CNS Cancer Diagnosis and Treatment
Molecular analysis is becoming crucial for identifying and treating complex central nervous system tumors, which traditional methods often miss, with companies like CNS Pharmaceuticals advancing targeted drug development.
Cybin Reports Strong Q2 2025 Results and Advances Late-Stage Neuropsychiatry Programs
Cybin Inc. has reported strong institutional demand in its second-quarter 2025 results while advancing multiple late-stage clinical programs for mental health treatments, positioning the company for key 2026 data readouts that could significantly impact neuropsychiatry treatment options.
Cybin to Present Neuropsychiatry Pipeline at Jefferies Global Healthcare Conference
Cybin Inc. will present its late-stage neuropsychiatry pipeline including breakthrough-designated depression treatment at the Jefferies Global Healthcare Conference, highlighting the company's progress in developing novel mental health therapies.
HOPE Therapeutics Launches Revolutionary One-Day Depression Treatment Protocol in Florida
NRx Pharmaceuticals' subsidiary HOPE Therapeutics has initiated Florida's first deployment of a rapid one-day TMS protocol for treatment-resistant depression, potentially transforming care for millions suffering from depression and PTSD.
Annovis Bio Completes Site Activation and Marks First Patient Completions in Pivotal Alzheimer's Phase 3 Trial
Annovis Bio has fully activated all 84 U.S. sites for its pivotal Phase 3 Alzheimer's trial and achieved first patient completions, positioning the company to deliver symptomatic data by late 2026 for its potential neurodegenerative disease therapy buntanetap.
Cybin Inc. to Present at Guggenheim Healthcare Innovation Conference Amid Phase 3 Mental Health Drug Development
Cybin Inc. announced its participation in the Guggenheim Healthcare Innovation Conference as the company advances its Phase 3 clinical trials for novel mental health treatments, highlighting growing investor interest in innovative neuropsychiatry solutions.
Cybin Chief Medical Officer to Present at Prestigious 2025 Milken Institute Health Summit
Cybin Inc.'s Chief Medical Officer will participate in the 2025 Milken Institute Future of Health Summit, highlighting the company's advanced clinical-stage mental health treatments and their potential to address significant unmet medical needs.
Study Reveals Chemotherapy May Damage Brain's Waste Drainage System, Explaining 'Chemo Brain' Symptoms
New research identifies chemotherapy-induced damage to the brain's waste drainage network as a potential cause of cognitive difficulties affecting up to 75% of cancer patients during and after treatment.
Annovis Bio Secures $3.4 Million in Registered Direct Offering to Advance Neurodegenerative Disease Therapies
Annovis Bio has raised $3.4 million through a registered direct offering to fund development of treatments for Alzheimer's and Parkinson's diseases, providing crucial capital for advancing late-stage clinical programs targeting neurodegeneration.
Alpha Cognition to Present at Spartan Capital Investor Conference, Highlighting Neurodegenerative Disease Treatments
Alpha Cognition's participation in the Spartan Capital Securities investor conference provides a platform to showcase its innovative treatments for Alzheimer's and cognitive impairment from traumatic brain injury, potentially attracting crucial investment for addressing unmet medical needs.
Quirkitude Releases Book on Ancient Herbal Remedies for Neurodivergent Wellness
Quirkitude's new book combines ancestral herbal wisdom with modern science to provide natural alternatives for stress, anxiety, and neurodivergent balance, addressing growing demand for holistic mental health approaches.
NRx Pharmaceuticals to Present Depression Treatment Advancements at Noble Capital Markets Conference
NRx Pharmaceuticals will present its innovative depression treatments including a low-dose D-Cycloserine product that enhances Transcranial Magnetic Stimulation effectiveness and discuss expanded clinical operations and VA collaborations for treating suicidal depression and PTSD.